Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain
1Health Value, Madrid, Spain, 2La Paz Hospital, Madrid, Spain, 3Consorci Mar Parc de Salut, Barcelona, Spain, 4Puerta de Hierro Mahadahonda Hospital, Madrid, Spain, 5Biohope Scientific Solutions for Human Health SL, Madrid, Spain
Meeting: 2020 American Transplant Congress
Abstract number: C-219
Keywords: Economics, Immunosuppression, Kidney transplantation, Monitoring
Session Information
Session Name: Poster Session C: Non-Organ Specific: Economics & Ethics
Session Type: Poster Session
Date: Saturday, May 30, 2020
Session Time: 3:15pm-4:00pm
Presentation Time: 3:30pm-4:00pm
Location: Virtual
*Purpose: Immunobiogram (IMBG) is a new IVD bioassay developed by Biohope SL with the aim to support clinicians in the personalized adjustment of immunosuppressive therapy in kidney transplant (KT) recipients. IMBG provides the sensitivity/resistance profile of each patient to a panel of immunosuppressive drugs (IS). The objective was to estimate the economic impact of IMBG use for National-Health-System in Spain.
*Methods: A probabilistic second-order Monte Carlo simulation was applied to a hypothetical cohort of 1,000 patients at least one year after the KT. Two scenarios were considered: graft failure in patients with high-immunological risk (HR) and adverse events (AEs) incidence in stable patients (non-HR). For a time-horizon of 5 years, we assumed one annual IMBG to be performed on HR patients and only one IMBG in total in the follow-up of non-HR patients. The probability of reducing the risk of graft failure by selecting the most effective IS/dose in HR patients with an IMBG resistant profile to the IS they are taking, and the probability of reducing AEs rate due to IS/dose adjustment in non-HR patients with an IMBG sensitive profile were obtained from a clinical study with IMBG and a systematic literature review and validated by a Spanish clinical experts panel. The costs associated with graft failure, IS therapy and AEs management were obtained from Spanish sources.
*Results: IMBG use may entail an estimated risk reduction of graft failure with a saving per HR patient of € 20,279 (95% CI € 17,512-23,105) and a 100% saving probability and an expected reduction in AE rate with savings per non-HR patient of € 3,328 (95% CI € 451-7,957) and a 99.5 saving probability. Considering both populations (HR and non-HR), the savings per patient would be € 7,098 (95% CI € 6,129-8,087), with a 99.7% saving probability.
*Conclusions: Immunobiogram estimated risk reductions of renal graft failure and AEs associated due to a personalized adjustment of immunosuppressive therapy could have considerable savings for the Spanish National-Health-System.
To cite this abstract in AMA style:
Rubio C, Jiménez C, Crespo M, Portolés J, Rubio D, Diez T, Portero I. Evaluation of the Economic Impact of a New IVD Immunoassay (Immunobiogram) for Immunosuppressive Treatment Adjustment in Kidney Transplant Recipients in Spain [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/evaluation-of-the-economic-impact-of-a-new-ivd-immunoassay-immunobiogram-for-immunosuppressive-treatment-adjustment-in-kidney-transplant-recipients-in-spain/. Accessed June 4, 2025.« Back to 2020 American Transplant Congress